Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Table 5

The endocrine and metabolic assessment of patients before and after administration of Tracnil™.

Group	Dehydroepiandrosterone sulfate (μg/dl)	Prolactin (ng/ml)	Insulin fasting serum (μU/ml)	Glucose fasting serum (mg/dl)
Before	128.7 ± 13.8	11.91 ± 1.27	7.048 ± 0.860	91.44 ± 2.14
After	119.9 ± 14.1	9.82 ± 1	9.58 ± 1.78	82.32 ± 3.04

Data shown as mean ± SEM for a sample size of N = 32 patients. Student’s t-test indicated no difference () between the levels of each group before and after treatment. Student’s t-test indicated significant difference () in the levels of each group before and after treatment.